Citigroup’s Protalix BioTherapeutics PLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $6.42K | Buy |
2,958
+1,324
| +81% | +$3.29K | ﹤0.01% | 5190 |
|
|
2025
Q4 | $2.94K | Sell |
1,634
-4,980
| -75% | -$10.2K | ﹤0.01% | 5387 |
|
|
2025
Q3 | $14.7K | Sell |
6,614
-18,142
| -73% | -$29.5K | ﹤0.01% | 4910 |
|
|
2025
Q2 | $36.6K | Buy |
24,756
+22,464
| +980% | +$46K | ﹤0.01% | 4910 |
|
|
2025
Q1 | $5.87K | Buy |
2,292
+1,660
| +263% | +$3.96K | ﹤0.01% | 5259 |
|
|
2024
Q4 | $1.19K | Buy |
+632
| New | +$894 | ﹤0.01% | 5586 |
|
|
2024
Q3 | – | Sell |
-1,307
| Closed | -$1.53K | – | 5775 |
|
|
2024
Q2 | $1.53K | Sell |
1,307
-11,424
| -90% | -$13.5K | ﹤0.01% | 5351 |
|
|
2024
Q1 | $16K | Buy |
12,731
+1,180
| +10% | +$1.76K | ﹤0.01% | 5095 |
|
|
2023
Q4 | $20.6K | Buy |
11,551
+9,658
| +510% | +$15K | ﹤0.01% | 4982 |
|
|
2023
Q3 | $3.14K | Sell |
1,893
-16,550
| -90% | -$29.7K | ﹤0.01% | 4846 |
|
|
2023
Q2 | $36.9K | Buy |
+18,443
| New | +$43.9K | ﹤0.01% | 4785 |
|
|
2022
Q2 | – | Sell |
-300
| Closed | – | – | 6560 |
|
|
2022
Q1 | $0 | Buy |
+300
| New | +$275 | ﹤0.01% | 6544 |
|
|
2018
Q1 | – | Sell |
-1,310
| Closed | -$9K | – | 7636 |
|
|
2017
Q4 | $9K | Hold |
1,310
| – | – | ﹤0.01% | 7076 |
|
|
2017
Q3 | $8K | Hold |
1,310
| – | – | ﹤0.01% | 6754 |
|
|
2017
Q2 | $11K | Buy |
+1,310
| New | +$12.3K | ﹤0.01% | 6497 |
|
|
2017
Q1 | – | Sell |
-58,479
| Closed | -$260K | – | 7303 |
|
|
2016
Q4 | $260K | Buy |
+58,479
| New | +$261K | ﹤0.01% | 5061 |
|
|
2016
Q2 | – | Sell |
-2
| Closed | – | – | 7339 |
|
|
2016
Q1 | $0 | Hold |
2
| – | – | ﹤0.01% | 7687 |
|
|
2015
Q4 | $0 | Hold |
2
| – | – | ﹤0.01% | 7795 |
|
|
2015
Q3 | $0 | Hold |
2
| – | – | ﹤0.01% | 7631 |
|
|
2015
Q2 | $0 | Hold |
2
| – | – | ﹤0.01% | 7690 |
|
|
2015
Q1 | $0 | Hold |
2
| – | – | ﹤0.01% | 7369 |
|
|
2014
Q4 | $0 | Sell |
2
-15
| -88% | -$322 | ﹤0.01% | 7260 |
|
|
2014
Q3 | $0 | Sell |
17
-40
| -70% | -$1.15K | ﹤0.01% | 7240 |
|
|
2014
Q2 | $2K | Sell |
57
-25
| -30% | -$1.01K | ﹤0.01% | 6766 |
|
|
2014
Q1 | $3K | Sell |
82
-174
| -68% | -$8.12K | ﹤0.01% | 6714 |
|
|
2013
Q4 | $10K | Hold |
256
| – | – | ﹤0.01% | 6419 |
|
|
2013
Q3 | $11K | Buy |
256
+168
| +191% | +$8.63K | ﹤0.01% | 6172 |
|
|
2013
Q2 | $4K | Buy |
+88
| New | +$4.67K | ﹤0.01% | 6386 |
|
Other funds holding PLX
MCO
SWP
VPM
PFS
OM
Citigroup's PLX Position: Q1 2026 in Review
Citigroup increased its Protalix BioTherapeutics (PLX) stake by 81% in Q1 2026, buying an estimated $3.29K and bringing the position to 2,958 shares worth $6.42K. The position accounts for ﹤0.01% of the portfolio, ranked #5190.
Citigroup first reported a position in PLX in Q2 2013 and has held it in 28 quarters since. The position peaked at $260K in Q4 2016. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.
- Citigroup held 2,958 shares of Protalix BioTherapeutics worth $6.42K as of Q1 2026.
- Citigroup bought 1,324 Protalix BioTherapeutics shares in Q1 2026, an estimated $3.29K.
- Protalix BioTherapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5190 holding.
- Citigroup first reported a position in Protalix BioTherapeutics in Q2 2013 and has held it in 28 quarters since.
- Citigroup's Protalix BioTherapeutics position peaked at $260K in Q4 2016.
- 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.